Logo image of SGMO

SANGAMO THERAPEUTICS INC (SGMO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SGMO - US8006771062 - Common Stock

0.4441 USD
+0 (+0.93%)
Last: 1/6/2026, 8:00:02 PM
0.4428 USD
0 (-0.29%)
Pre-Market: 1/7/2026, 5:41:55 AM
Fundamental Rating

2

SGMO gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. The financial health of SGMO is average, but there are quite some concerns on its profitability. While showing a medium growth rate, SGMO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SGMO had negative earnings in the past year.
SGMO had a negative operating cash flow in the past year.
In the past 5 years SGMO always reported negative net income.
SGMO had negative operating cash flow in 4 of the past 5 years.
SGMO Yearly Net Income VS EBIT VS OCF VS FCFSGMO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M

1.2 Ratios

With a Return On Assets value of -122.86%, SGMO is not doing good in the industry: 79.25% of the companies in the same industry are doing better.
SGMO has a worse Return On Equity (-1744.50%) than 80.38% of its industry peers.
Industry RankSector Rank
ROA -122.86%
ROE -1744.5%
ROIC N/A
ROA(3y)-95.5%
ROA(5y)-64.82%
ROE(3y)-268.79%
ROE(5y)-175.64%
ROIC(3y)N/A
ROIC(5y)N/A
SGMO Yearly ROA, ROE, ROICSGMO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

SGMO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SGMO Yearly Profit, Operating, Gross MarginsSGMO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

More info and screens

4

2. Health

2.1 Basic Checks

SGMO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SGMO has been increased compared to 1 year ago.
Compared to 5 years ago, SGMO has more shares outstanding
SGMO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SGMO Yearly Shares OutstandingSGMO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
SGMO Yearly Total Debt VS Total AssetsSGMO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of -27.79, we must say that SGMO is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of SGMO (-27.79) is worse than 85.85% of its industry peers.
SGMO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -27.79
ROIC/WACCN/A
WACC8.81%
SGMO Yearly LT Debt VS Equity VS FCFSGMO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 0.88 indicates that SGMO may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.88, SGMO is doing worse than 86.98% of the companies in the same industry.
SGMO has a Quick Ratio of 0.88. This is a bad value and indicates that SGMO is not financially healthy enough and could expect problems in meeting its short term obligations.
SGMO has a worse Quick ratio (0.88) than 86.60% of its industry peers.
Industry RankSector Rank
Current Ratio 0.88
Quick Ratio 0.88
SGMO Yearly Current Assets VS Current LiabilitesSGMO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 41.33% over the past year.
SGMO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -37.70%.
Measured over the past years, SGMO shows a very negative growth in Revenue. The Revenue has been decreasing by -10.81% on average per year.
EPS 1Y (TTM)41.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-375%
Revenue 1Y (TTM)-37.7%
Revenue growth 3Y-19.48%
Revenue growth 5Y-10.81%
Sales Q2Q%-98.82%

3.2 Future

The Earnings Per Share is expected to grow by 22.96% on average over the next years. This is a very strong growth
SGMO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 38.32% yearly.
EPS Next Y31.21%
EPS Next 2Y16.31%
EPS Next 3Y16.03%
EPS Next 5Y22.96%
Revenue Next Year-11.31%
Revenue Next 2Y-15.32%
Revenue Next 3Y29.21%
Revenue Next 5Y38.32%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SGMO Yearly Revenue VS EstimatesSGMO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
SGMO Yearly EPS VS EstimatesSGMO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SGMO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SGMO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SGMO Price Earnings VS Forward Price EarningsSGMO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SGMO Per share dataSGMO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

A more expensive valuation may be justified as SGMO's earnings are expected to grow with 16.03% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.31%
EPS Next 3Y16.03%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SGMO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

SANGAMO THERAPEUTICS INC

NASDAQ:SGMO (1/6/2026, 8:00:02 PM)

Premarket: 0.4428 0 (-0.29%)

0.4441

+0 (+0.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)03-16 2026-03-16/amc
Inst Owners18.72%
Inst Owner Change0%
Ins Owners1.31%
Ins Owner Change-5.69%
Market Cap149.44M
Revenue(TTM)32.88M
Net Income(TTM)-108.91M
Analysts78.33
Price Target3.32 (647.58%)
Short Float %6%
Short Ratio3.09
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-31749.3%
Min EPS beat(2)-63537.1%
Max EPS beat(2)38.49%
EPS beat(4)1
Avg EPS beat(4)-15880.5%
Min EPS beat(4)-63537.1%
Max EPS beat(4)38.49%
EPS beat(8)2
Avg EPS beat(8)-7919.96%
EPS beat(12)4
Avg EPS beat(12)-5281.72%
EPS beat(16)8
Avg EPS beat(16)-3957.71%
Revenue beat(2)0
Avg Revenue beat(2)-70.85%
Min Revenue beat(2)-98.34%
Max Revenue beat(2)-43.35%
Revenue beat(4)0
Avg Revenue beat(4)-50.56%
Min Revenue beat(4)-98.34%
Max Revenue beat(4)-14.91%
Revenue beat(8)1
Avg Revenue beat(8)-37.03%
Revenue beat(12)2
Avg Revenue beat(12)15.02%
Revenue beat(16)5
Avg Revenue beat(16)12.37%
PT rev (1m)0%
PT rev (3m)-20.73%
EPS NQ rev (1m)-12.52%
EPS NQ rev (3m)34.35%
EPS NY rev (1m)-4.74%
EPS NY rev (3m)-20.43%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)54.02%
Revenue NY rev (1m)-6.6%
Revenue NY rev (3m)-26.3%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.55
P/FCF N/A
P/OCF N/A
P/B 23.94
P/tB 23.94
EV/EBITDA N/A
EPS(TTM)-0.44
EYN/A
EPS(NY)-0.34
Fwd EYN/A
FCF(TTM)-0.23
FCFYN/A
OCF(TTM)-0.23
OCFYN/A
SpS0.1
BVpS0.02
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -122.86%
ROE -1744.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-95.5%
ROA(5y)-64.82%
ROE(3y)-268.79%
ROE(5y)-175.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 5.66%
Cap/Sales 0.73%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.88
Quick Ratio 0.88
Altman-Z -27.79
F-Score4
WACC8.81%
ROIC/WACCN/A
Cap/Depr(3y)104.2%
Cap/Depr(5y)163.67%
Cap/Sales(3y)10.21%
Cap/Sales(5y)12.82%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-375%
EPS Next Y31.21%
EPS Next 2Y16.31%
EPS Next 3Y16.03%
EPS Next 5Y22.96%
Revenue 1Y (TTM)-37.7%
Revenue growth 3Y-19.48%
Revenue growth 5Y-10.81%
Sales Q2Q%-98.82%
Revenue Next Year-11.31%
Revenue Next 2Y-15.32%
Revenue Next 3Y29.21%
Revenue Next 5Y38.32%
EBIT growth 1Y35.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year28.95%
EBIT Next 3Y-31.75%
EBIT Next 5Y34.36%
FCF growth 1Y70.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y67.07%
OCF growth 3YN/A
OCF growth 5YN/A

SANGAMO THERAPEUTICS INC / SGMO FAQ

What is the ChartMill fundamental rating of SANGAMO THERAPEUTICS INC (SGMO) stock?

ChartMill assigns a fundamental rating of 2 / 10 to SGMO.


What is the valuation status for SGMO stock?

ChartMill assigns a valuation rating of 0 / 10 to SANGAMO THERAPEUTICS INC (SGMO). This can be considered as Overvalued.


Can you provide the profitability details for SANGAMO THERAPEUTICS INC?

SANGAMO THERAPEUTICS INC (SGMO) has a profitability rating of 0 / 10.